Trevi Therapeutics: The Code Against Chronic Cough

Trevi Therapeutics has approximately 334 million USD in liquid assets thanks to successful capital increases, meaning the company is fully financed until 2030 and is not at risk of short-term dilution. With the promising candidate Haduvio , the company is aiming for a potential approval monopoly in an untapped billion-dollar market for chronic cough. Despite top-notch study data, the stock remains a highly speculative bet for risk-seeking investors. The U.S. biotech stock Trevi Therapeutics (NASDAQ: TRVI) is surging from one high to another...